CTMXHealthcare · BiotechnologyThe 8 Wall Street analysts covering CytomX Therapeutics, Inc. hold a median 12-month price target of $12 — +264.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 47 of 100 as at 10 Sept 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores CytomX Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (71): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Growth (17): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CTMX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +264.7% from it.
Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Aug 2026 | JP Morgan | Maintains | Overweight | $12 → $11 |
| 10 Aug 2026 | Guggenheim | Maintains | Buy | $15 → $14 |
| 11 May 2026 | HC Wainwright & Co. | Maintains | Buy | $17 → $11 |
| 11 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 23 Mar 2026 | Piper Sandler | Maintains | Overweight | — |
| 19 Mar 2026 | Barclays | Maintains | Overweight | — |
| 18 Mar 2026 | Guggenheim | Maintains | Buy | — |
| 18 Mar 2026 | Jefferies | Maintains | Buy | — |
| 17 Mar 2026 | Wedbush | Maintains | Outperform | — |
| 16 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 16 Mar 2026 | JP Morgan | Upgrade | Overweight | — |
| 9 Mar 2026 | Guggenheim | Reiterates | Buy | — |
| 4 Feb 2026 | Barclays | Maintains | Overweight | — |
| 4 Feb 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 20 Jan 2026 | Barclays | Maintains | Overweight | — |
| 20 Jan 2026 | Guggenheim | Initiates | Buy | — |
| 20 Jan 2026 | Piper Sandler | Maintains | Overweight | — |
| 11 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 21 Oct 2025 | Barclays | Maintains | Overweight | — |
| 22 Sept 2025 | Cantor Fitzgerald | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CTMX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, CytomX Therapeutics, Inc. returned +57.4% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 44% of US stocks
Cheaper than 6% of US stocks
Cheaper than 39% of US stocks
Cheaper than 79% of US stocks
Higher than 2% of US stocks
Higher than 3% of US stocks
Higher than 4% of US stocks
Higher than 30% of US stocks
Higher than 25% of US stocks
Higher than 20% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
CytomX Therapeutics, Inc. has a market value of $730.0M and an enterprise value of $446.8M.
Revenue in the twelve months to 30 June 2026: $18.3M. The latest quarter shrank 92.4% year on year.
Net income over the same four quarters: −$79.7M, a −435.2% net margin.
Free cash flow in the twelve months to 30 June 2026: −$82.5M.
Trailing P/E: 15.9×; forward P/E: −7.1× — the forward figure prices analyst consensus estimates, not reported earnings.
CytomX Therapeutics, Inc. employs 69 people — $265K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own CytomX Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
CytomX Therapeutics announced that its management will participate in several investor conferences scheduled for September. The announcement outlines upcoming conference appearances but provides no other details.
Why it matters — The conference presentations could raise visibility for CytomX among investors and provide updates on its masked, conditionally activated biologics platform.
CytomX Therapeutics announced that the FDA has granted Fast Track Designation to Varseta-M for the treatment of patients with relapsed/refractory metastatic colorectal cancer. The designation follows encouraging Phase 1 data, and a potential Varseta-M monotherapy registrational study in R/R mCRC is planned to begin in the first half of 2027.
Why it matters — Fast Track Designation for Varseta-M could help expedite development of a lead candidate for an area of unmet need, and CTMX watchers will track the planned 2027 registrational study.
A Seeking Alpha article discusses CytomX Therapeutics' PROBODY platform and its lead asset Varseta-M, noting early colorectal cancer activity but stressing the need for larger and more mature datasets. It highlights upcoming data catalysts, including a Varseta-M monotherapy update, combination-study data, and new gastrointestinal cohorts through the first half of 2027.
Why it matters — A CTMX watcher would care because the article outlines several near-term pipeline catalysts from Varseta-M and the PROBODY platform that could shape the company's outlook.
CytomX Therapeutics held its Q2 2026 earnings call, and Seeking Alpha published a transcript of the event. The excerpt contains only the headline and attribution identifying the transcript's availability.
Why it matters — The Q2 2026 earnings call transcript provides CTMX watchers with direct insight into the company's latest quarterly results and management commentary.
CytomX Therapeutics reported that its second-quarter focus centered on advancing Varseta-M, an EpCAM-targeting antibody-drug conjugate for metastatic colorectal cancer, while expanding the program into combination regimens and additional gastrointestinal cancers.
Why it matters — The update highlights management's continued commitment to advancing Varseta-M, the company's key pipeline asset, and its expansion into new indications.
The 8 Wall Street analysts covering CytomX Therapeutics, Inc. have a median 12-month price target of $12, with estimates ranging from $6 to $16. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering CytomX Therapeutics, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CytomX Therapeutics, Inc. 47 out of 100 across roughly 4,600 US stocks as at 10 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 10 Sept 2026, CytomX Therapeutics, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (71 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +264.7% from the last close, and Ticker Nerd's factor model ranks CytomX Therapeutics, Inc. 47 out of 100 as at 10 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering CytomX Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CTMX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $16 over the next 12 months.
CytomX Therapeutics, Inc. returned +57.4% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology.
The most recent item we track (GlobeNewsWire, 1 Sept 2026): "CytomX Therapeutics to Present at Upcoming September Investor Conferences". CytomX Therapeutics announced that its management will participate in several investor conferences scheduled for September. The announcement outlines upcoming conference appearances but provides no other details.
CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology. The company develops conditionally activated biologics through its Probody therapeutic platform, with the goal of localizing activity to the tumor microenvironment and limiting effects on healthy tissue. Its current pipeline spans multiple cancer-focused modalities, including antibody-drug conjugates, T-cell engagers, and immune-modulating therapies such as cytokines. CytomX Therapeutics also advances programs aimed at difficult-to-treat tumors, supporting research and development across a range of solid-tumor indications. Headquartered in South San Francisco, California, CytomX Therapeutics plays a specialized role in the biotechnology market as a developer of targeted cancer therapeutics designed for precision and selectivity.
CEO Dr. Sean A. McCarthy DPHIL · 69 employees · United States · https://www.cytomx.com
